Delving into the Latest Updates on Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd. specializes in the development of novel functional molecules aimed at treating metabolic and immune-related organ diseases. The company prides itself on its innovative and professional team and its platform, representing the latest strategic move by Fosun Pharma Group in the field of global pharmaceutical innovation.

Tags

Cardiovascular Diseases

Nervous System Diseases

Immune System Diseases

Small molecule drug

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	3
Nervous System Diseases	2
Neoplasms	2
Infectious Diseases	2
Endocrinology and Metabolic Disease	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Antibody	1

Top 5 Target	Count

MAPKAPK2(MAP kinase-activated protein kinase 2)	1
TPL2(Mitogen-activated protein kinase kinase kinase 8)	1
CFB(Complement factor B)	1

(1) 定量分析男性健康受试者单次口服[14C]XH-S004后排泄物中的总放射性，获得人体放射性排泄率数据和主要排泄途径； (2) 定量分析男性健康受试者单次口服[14C]XH-S004后人血浆、尿液和粪便的放射性代谢物谱，鉴定主要代谢产物，确定XH-S004在人体内的代谢途径及消除途径； (3) 定量分析男性健康受试者单次口服[14C]XH-S004后全血和血浆中的总放射性，获得血浆和全血（如适用）总放射性的药代动力学参数，并考察全血和血浆中总放射性的分配情况。

[Translation]

(1) Quantitative analysis of the total radioactivity in the excreta of male healthy subjects after a single oral administration of [14C]XH-S004, to obtain data on the excretion rate of radioactivity in humans and the main excretion pathways; (2) Quantitative analysis of the radioactive metabolite profiles in human plasma, urine, and feces of male healthy subjects after a single oral administration of [14C]XH-S004, to identify the main metabolites, and to determine the metabolic pathways and elimination pathways of XH-S004 in humans; (3) Quantitative analysis of the total radioactivity in whole blood and plasma of male healthy subjects after a single oral administration of [14C]XH-S004, to obtain pharmacokinetic parameters of the total radioactivity in plasma and whole blood (if applicable), and to investigate the distribution of the total radioactivity in whole blood and plasma.

Start Date-

Sponsor / Collaborator

Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.

CTR20253273

/ Not yet recruitingPhase 1

[14C]XH-S003在健康受试者中的物质平衡研究

[Translation] Study on the Material Balance of [14C]XH-S003 in Healthy Subjects

(1) 定量分析男性健康受试者单次口服[14C]XH-S003后排泄物中的总放射性，获得人体放射性回收率数据和主要排泄途径； (2) 定量分析男性健康受试者单次口服[14C]XH-S003后人血浆、尿液和粪便的放射性代谢物谱，鉴定主要代谢产物，确定XH-S003在人体内的代谢途径及消除途径； (3) 定量分析男性健康受试者单次口服[14C]XH-S003后全血和血浆中的总放射性，获得血浆和全血（如适用）总放射性的药代动力学参数，并考察全血和血浆中总放射性的分配情况。

[Translation]

(1) Quantitative analysis of the total radioactivity in the excreta of healthy male subjects after a single oral administration of [14C]XH-S003, to obtain the human radioactivity recovery rate data and the main excretion pathway; (2) Quantitative analysis of the radioactive metabolite profiles in human plasma, urine, and feces of healthy male subjects after a single oral administration of [14C]XH-S003, to identify the main metabolites, and to determine the metabolic pathways and elimination pathways of XH-S003 in the human body; (3) Quantitative analysis of the total radioactivity in whole blood and plasma of healthy male subjects after a single oral administration of [14C]XH-S003, to obtain the pharmacokinetic parameters of the total radioactivity in plasma and whole blood (if applicable), and to investigate the distribution of the total radioactivity in whole blood and plasma.

Start Date-

Sponsor / Collaborator

Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 1

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

XH-S003 ( CFB )	Glomerulonephritis, IGA More	Phase 2
XH-S002	Ischemic stroke More	Phase 1
FS-2101	COVID-19 More	Preclinical
WO2025020886 ( TPL2 )Patent Mining	Nervous System Diseases More	Discovery
WO2025092739 ( MAPKAPK2 )Patent Mining	Atherosclerosis More	Discovery